Bone metabolism in Langerhans cell histiocytosis
- PMID: 29967185
- PMCID: PMC6063875
- DOI: 10.1530/EC-18-0186
Bone metabolism in Langerhans cell histiocytosis
Abstract
Langerhans cell histiocytosis (LCH) is a rare disease of not well-defined etiology that involves immune cell activation and frequently affects the skeleton. Bone involvement in LCH usually presents in the form of osteolytic lesions along with low bone mineral density. Various molecules involved in bone metabolism are implicated in the pathogenesis of LCH or may be affected during the course of the disease, including interleukins (ILs), tumor necrosis factor α, receptor activator of NF-κB (RANK) and its soluble ligand RANKL, osteoprotegerin (OPG), periostin and sclerostin. Among them IL-17A, periostin and RANKL have been proposed as potential serum biomarkers for LCH, particularly as the interaction between RANK, RANKL and OPG not only regulates bone homeostasis through its effects on the osteoclasts but also affects the activation and survival of immune cells. Significant changes in circulating and lesional RANKL levels have been observed in LCH patients irrespective of bone involvement. Standard LCH management includes local or systematic administration of corticosteroids and chemotherapy. Given the implication of RANK, RANKL and OPG in the pathogenesis of the disease and the osteolytic nature of bone lesions, agents aiming at inhibiting the RANKL pathway and/or osteoclastic activation, such as bisphosphonates and denosumab, may have a role in the therapeutic approach of LCH although further clinical investigation is warranted.
Keywords: Langerhans cell histiocytosis (LCH); bisphosphonates; denosumab; osteoporosis; receptor activator of NF-κB ligand (RANKL).
© 2018 The authors.
Figures
References
-
- Arico M, Girschikofsky M, Genereau T, Klersy C, McClain K, Grois N, Emile JF, Lukina E, De Juli E, Danesino C. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. European Journal of Cancer 2003. 39 2341–2348. (10.1016/S0959-8049(03)00672-5) - DOI - PubMed
-
- Girschikofsky M, Arico M, Castillo D, Chu A, Doberauer C, Fichter J, Haroche J, Kaltsas GA, Makras P, Marzano AV, et al. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet Journal of Rare Diseases 2013. 8 72 (10.1186/1750-1172-8-72) - DOI - PMC - PubMed
-
- PDQ Pediatric Treatment Editorial Board. Langerhans Cell Histiocytosis Treatment (PDQ®): Health Professional Version. PDQ Cancer Information Summaries. Bethesda, MD, USA: National Cancer Institute (US), 2017. (available at: https://www.ncbi.nlm.nih.gov/books/NBK65799/) - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
